文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性阿柏西普治疗期间视力丧失的发生率与原因:一年随访

INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: One-Year Follow-up.
PubMed 文献 · Retina · 2017-01-01

前瞻性招募196例未治疗的新生血管性年龄相关性黄斑变性患者,接受阿柏西普每月三次后每两月一次注射治疗,16例(8.2%)出现视力丧失,其中11例发生在初始3个月内,最终随访时11眼视力丧失持续存在,最大色素上皮脱离高度和外界膜断裂为危险因素。

要点

  • 阿柏西普治疗期间视力丧失发生率为8.2%(16/196例),其中68.8%(11/16)发生在初始3个月内。
  • 最终随访时68.8%(11/16)视力丧失持续存在。
  • 最大色素上皮脱离高度(每增加100μm,OR=1.46)和外界膜断裂(OR=4.45)是视力丧失的危险因素。

核心结论

  • 阿柏西普治疗期间视力丧失发生率相对较低,识别高色素上皮脱离高度和外界膜断裂的高危患者有助于治疗前充分知情同意,需进一步研究确立最佳治疗方案。

研究设计与样本

  • 前瞻性招募未治疗的新生血管性年龄相关性黄斑变性患者,接受阿柏西普每月三次注射后每两月一次注射治疗,共纳入196例患者的196眼。

主要发现

  • 16例患者(8.2%)出现视力丧失,其中11例(68.8%)发生在初始3个月内。
  • 最终随访时11眼(68.8%)视力丧失持续存在。
  • 逻辑回归分析显示最大色素上皮脱离高度(每增加100μm,OR=1.46)和外界膜断裂(OR=4.45)是视力丧失的危险因素。

关键数值与推荐

  • 视力丧失定义为任意访视时视力下降超过两行。
  • 最大色素上皮脱离高度每增加100μm的OR=1.46,外界膜断裂的OR=4.45。

临床怎么用

  • 识别高色素上皮脱离高度和外界膜断裂的高危患者,有助于治疗前确保适当的知情同意。

局限性

  • 需进一步研究以确立这些患者的最佳治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence rate, risk factors, and final outcomes of patients with age-related macular degeneration (AMD) who have experienced vision loss despite periodic aflibercept treatment. METHODS: Subjects with treatment-naive AMD were prospectively recruited and treated with three monthly injections followed by two monthly injections of aflibercept. The incidence rate and risk factors of more than two lines of vision loss at any visit were investigated. RESULTS: We included 196 eyes of 196 patients. Vision loss was observed in 16 patients (8.2%). Eleven of 16 patients developed vision loss during the initial 3 months (68.8%). Vision loss remained in 11 eyes (68.8%) at the final visit. The maximum pigment epithelium detachment (PED) height (odds ratio = 1.46 for a 100-μm increase in the PED height) and disruption of the external limiting membrane (odds ratio = 4.45) were identified as risk factors for developing vision loss on logistic regression analysis. CONCLUSION: The incidence rate of vision loss during aflibercept treatment was relatively low. Identifying high-risk patients, those with a high PED height and disruption of the external limiting membrane, would be helpful in ensuring appropriate informed consent before treatment. Further studies are needed to establish optimal treatment for these patients.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Hata M, Oishi A, Yamashiro K, et al. INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: One-Year Follow-up. Retina. 2017. PMID: 27787445. doi:10.1097/IAE.0000000000001370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。